

Peptidyl-prolyl cis/trans isomerases in GtoPdb v.2025.3

Stephanie Annett¹ and Tracy Robson¹

1. RCSI, University of Medicine and Health Sciences, Ireland

Abstract

Peptidyl-prolyl cis/trans isomerases (PPIases) are an enzyme family which catalyse the cis/trans isomerisation of proline peptide bonds to promote the folding and re-folding of peptides and proteins. Three subfamilies have been identified: cyclophilins, FK506-binding proteins and parvulins. Individual PPIases are overexpressed in a number of cancers [65], and family members have been targeted for immunosuppressant effects.

Contents

This is a citation summary for Peptidyl-prolyl cis/trans isomerases in the [Guide to Pharmacology](#) database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links.

[GtoPdb](#) is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. For further details see [10].

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

Database links

Peptidyl-prolyl cis/trans isomerases

<https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=845>

Introduction to Peptidyl-prolyl cis/trans isomerases

<https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=845>

Enzymes

FKBP12(FKBP prolyl isomerase 1A)

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2609>

FKBP38(FKBP prolyl isomerase 8)

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3177>

FKBP51(FKBP prolyl isomerase 5)

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3175>

FKBP52(FKBP prolyl isomerase 4)

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3176>

FKBP prolyl isomerase like

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3178>

peptidylprolyl cis/trans isomerase, NIMA-interacting 1

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3171>

Cyclophilin A(peptidylprolyl isomerase A)

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2751>

Cyclophilin D(peptidylprolyl isomerase D)

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3179>

References

1. Annett S, Moore G and Robson T. (2020) FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention. *Pharmacol Ther* **215**: 107623 [PMID:32622856]
2. Annett S, Moore G, Short A, Marshall A, McCrudden C, Yakkundi A, Das S, McCluggage WG, Nelson L and Harley I *et al.*. (2020) FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. *Br J Cancer* **122**: 361-371 [PMID:31772325]
3. Azzolin L, Antolini N, Calderan A, Ruzza P, Sciacovelli M, Marin O, Mammi S, Bernardi P and Rasola A. (2011) Antamanide, a derivative of *Amanita phalloides*, is a novel inhibitor of the mitochondrial permeability transition pore. *PLoS One* **6**: e16280 [PMID:21297983]
4. Banteli R, Wagner J and Zenke G. (2001) Synthesis of derivatives of the novel cyclophilin-binding immunosuppressant sanglifehrin A with reduced numbers of polar functions. *Bioorg Med Chem Lett* **11**: 1609-12 [PMID:11412991]
5. Barik S. (2018) Dual-Family Peptidylprolyl Isomerases (Immunophilins) of Select Monocellular Organisms. *Biomolecules* **8** [PMID:30445770]
6. Biasutto L, Azzolini M, Szabò I and Zoratti M. (2016) The mitochondrial permeability transition pore in AD 2016: An update. *Biochim Biophys Acta* **1863**: 2515-30 [PMID:26902508]
7. Blair LJ, Baker JD, Sabbagh JJ and Dickey CA. (2015) The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer's disease. *J Neurochem* **133**: 1-13 [PMID:25628064]
8. Bracher A, Kozany C, Hähle A, Wild P, Zacharias M and Hausch F. (2013) Crystal structures of the free and ligand-bound FK1-FK2 domain segment of FKBP52 reveal a flexible inter-domain hinge. *J Mol Biol* **425**: 4134-44 [PMID:23933011]
9. Briston T, Lewis S, Koglin M, Mistry K, Shen Y, Hartopp N, Katsumata R, Fukumoto H, Duchon MR and Szabadkai G *et al.*. (2016) Identification of ER-000444793, a Cyclophilin D-independent inhibitor of mitochondrial permeability transition, using a high-throughput screen in cryopreserved mitochondria. *Sci Rep* **6**: 37798 [PMID:27886240]
10. Buneman P, Christie G, Davies JA, Dimitrellou R, Harding SD, Pawson AJ, Sharman JL and Wu Y. (2020) Why data citation isn't working, and what to do about it *Database* **2020** [PMID:32367113]
11. Butterfield DA, Abdul HM, Opii W, Newman SF, Joshi G, Ansari MA and Sultana R. (2006) Pin1 in Alzheimer's disease. *J Neurochem* **98**: 1697-706 [PMID:16945100]
12. Christner C, Wyrwa R, Marsch S, Küllertz G, Thiericke R, Grabley S, Schumann D and Fischer G. (1999) Synthesis and cytotoxic evaluation of cycloheximide derivatives as potential inhibitors of FKBP12 with neuroregenerative properties. *J Med Chem* **42**: 3615-22 [PMID:10479292]
13. Clarke SJ, McStay GP and Halestrap AP. (2002) Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. *J Biol Chem* **277**: 34793-9 [PMID:12095984]
14. Donley C, McClelland K, McKeen HD, Nelson L, Yakkundi A, Jithesh PV, Burrows J, McClements L, Valentine A and Prise KM *et al.*. (2014) Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen. *Oncogene* **33**: 3441-50 [PMID:23912458]
15. Dube H, Selwood D, Malouitre S, Capano M, Simone MI and Crompton M. (2012) A mitochondrial-targeted cyclosporin A with high binding affinity for cyclophilin D yields improved cytoprotection of cardiomyocytes. *Biochem J* **441**: 901-7 [PMID:22035570]
16. Dubiella C, Pinch BJ, Koikawa K, Zaidman D, Poon E, Manz TD, Nabat B, He S, Resnick E and Rogel A *et al.*. (2021) Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. *Nat Chem Biol* **17**: 954-963 [PMID:33972797]
17. Dunyak BM and Gestwicki JE. (2016) Peptidyl-Proline Isomerases (PPIases): Targets for Natural Products and Natural Product-Inspired Compounds. *J Med Chem* **59**: 9622-9644 [PMID:27409354]
18. Edlich F, Erdmann F, Jarczowski F, Moutty MC, Weiwad M and Fischer G. (2007) The Bcl-2 regulator FKBP38-calmodulin-Ca²⁺ is inhibited by Hsp90. *J Biol Chem* **282**: 15341-8 [PMID:17379601]
19. Edlich F and Lücke C. (2011) From cell death to viral replication: the diverse functions of the membrane-associated FKBP38. *Curr Opin Pharmacol* **11**: 348-53 [PMID:21514222]
20. Edlich F, Weiwad M, Wildemann D, Jarczowski F, Kilka S, Moutty MC, Jahreis G, Lücke C, Schmidt W and Striggow F *et al.*. (2006) The specific FKBP38 inhibitor N-(N',N'-dimethylcarboxamidomethyl)cycloheximide has potent neuroprotective and neurotrophic properties in brain ischemia. *J Biol Chem* **281**: 14961-70 [PMID:16547004]
21. Elkamhawy A, Park JE, Hassan AHE, Pae AN, Lee J, Park BG and Roh EJ. (2018) Synthesis and evaluation of 2-(3-arylsureido)pyridines and 2-(3-arylsureido)pyrazines as potential modulators of Aβ-induced mitochondrial dysfunction in Alzheimer's disease. *Eur J Med Chem* **144**: 529-543 [PMID:29288949]

22. Erlejan AG, De Leo SA, Mazaira GI, Molinari AM, Camisay MF, Fontana V, Cox MB, Piwien-Pilipuk G and Galigniana MD. (2014) NF- κ B transcriptional activity is modulated by FK506-binding proteins FKBP51 and FKBP52: a role for peptidyl-prolyl isomerase activity. *J Biol Chem* **289**: 26263-26276 [PMID:25104352]
23. Esnault S, Shen ZJ and Malter JS. (2008) Pinning down signaling in the immune system: the role of the peptidyl-prolyl isomerase Pin1 in immune cell function. *Crit Rev Immunol* **28**: 45-60 [PMID:18298383]
24. Frausto SD, Lee E and Tang H. (2013) Cyclophilins as modulators of viral replication. *Viruses* **5**: 1684-701 [PMID:23852270]
25. Fruman DA, Klee CB, Bierer BE and Burakoff SJ. (1992) Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. *Proc Natl Acad Sci USA* **89**: 3686-90 [PMID:1373887]
26. Gaali S, Kirschner A, Cuboni S, Hartmann J, Kozany C, Balsevich G, Namendorf C, Fernandez-Vizarra P, Sippel C and Zannas AS *et al.*. (2015) Selective inhibitors of the FK506-binding protein 51 by induced fit. *Nat Chem Biol* **11**: 33-7 [PMID:25436518]
27. Garcia-Touchard A, Burke SE, Toner JL, Cromack K and Schwartz RS. (2006) Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. *Eur Heart J* **27**: 988-93 [PMID:16449248]
28. Gharthey-Kwansah G, Li Z, Feng R, Wang L, Zhou X, Chen FZ, Xu MM, Jones O, Mu Y and Chen S *et al.*. (2018) Comparative analysis of FKBP family protein: evaluation, structure, and function in mammals and *Drosophila melanogaster*. *BMC Dev Biol* **18**: 7 [PMID:29587629]
29. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P and Thompson A *et al.*. (2011) A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. *Cancer Cell* **20**: 79-91 [PMID:21741598]
30. Gopalakrishnan R, Kozany C, Wang Y, Schneider S, Hoogeland B, Bracher A and Hausch F. (2012) Exploration of pipecolate sulfonamides as binders of the FK506-binding proteins 51 and 52. *J Med Chem* **55**: 4123-31 [PMID:22455398]
31. Guo C, Hou X, Dong L, Marakovits J, Greasley S, Dagostino E, Ferre R, Johnson MC, Humphries PS and Li H *et al.*. (2014) Structure-based design of novel human Pin1 inhibitors (III): optimizing affinity beyond the phosphate recognition pocket. *Bioorg Med Chem Lett* **24**: 4187-91 [PMID:25091930]
32. Göthel SF and Marahiel MA. (1999) Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. *Cell Mol Life Sci* **55**: 423-36 [PMID:10228556]
33. Hamilton GS and Steiner JP. (1998) Immunophilins: beyond immunosuppression. *J Med Chem* **41**: 5119-43 [PMID:9857082]
34. Handschumacher RE, Harding MW, Rice J, Drugge RJ and Speicher DW. (1984) Cyclophilin: a specific cytosolic binding protein for cyclosporin A. *Science* **226**: 544-7 [PMID:6238408]
35. Hansson MJ, Mattiasson G, Månsson R, Karlsson J, Keep MF, Waldmeier P, Ruegg UT, Dumont JM, Besseghir K and Elmer E. (2004) The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. *J Bioenerg Biomembr* **36**: 407-13 [PMID:15377880]
36. Hultsch T, Müller KD, Meingassner JG, Grassberger M, Schopf RE and Knop J. (1998) Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. *Arch Dermatol Res* **290**: 501-7 [PMID:9808344]
37. Ji KY, Kim SM, Yee SM, Kim MJ, Ban YJ, Kim EM, Lee EH, Choi HR, Yun H and Lee CW *et al.*. (2021) Cyclophilin A is an endogenous ligand for the triggering receptor expressed on myeloid cells-2 (TREM2). *FASEB J* **35**: e21479 [PMID:33710680]
38. Khaspekov L, Friberg H, Halestrap A, Viktorov I and Wieloch T. (1999) Cyclosporin A and its nonimmunosuppressive analogue N-Me-Val-4-cyclosporin A mitigate glucose/oxygen deprivation-induced damage to rat cultured hippocampal neurons. *Eur J Neurosci* **11**: 3194-8 [PMID:10510183]
39. Knaup FH, Meyners C, Sugiarto WO, Wedel S, Springer M, Walz C, Geiger TM, Schmidt M, Sisignano M and Hausch F. (2023) Structure-Based Discovery of a New Selectivity-Enabling Motif for the FK506-Binding Protein 51. *J Med Chem* **66**: 5965-5980 [PMID:37058391]
40. Kolos JM, Voll AM, Bauder M and Hausch F. (2018) FKBP Ligands-Where We Are and Where to Go? *Front Pharmacol* **9**: 1425 [PMID:30568592]
41. Koren 3rd J, Jinwal UK, Davey Z, Kiray J, Arulselvam K and Dickey CA. (2011) Bending tau into shape: the emerging role of peptidyl-prolyl isomerases in tauopathies. *Mol Neurobiol* **44**: 65-70 [PMID:21523562]
42. Kuglstatte A, Mueller F, Kuszniir E, Gsell B, Stihle M, Thoma R, Benz J, Aspeslet L, Freitag D and Hennig M. (2011) Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin). *Acta Crystallogr D Biol Crystallogr* **67**: 119-23 [PMID:21245533]
43. Kuo J, Bobardt M, Chatterji U, Mayo PR, Trepanier DJ, Foster RT, Gallay P and Ure DR. (2019) A

- Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models. *J Pharmacol Exp Ther* **371**: 231-241 [PMID:31406003]
44. Lammers M, Neumann H, Chin JW and James LC. (2010) Acetylation regulates cyclophilin A catalysis, immunosuppression and HIV isomerization. *Nat Chem Biol* **6**: 331-7 [PMID:20364129]
 45. Liou YC, Sun A, Ryo A, Zhou XZ, Yu ZX, Huang HK, Uchida T, Bronson R, Bing G and Li X *et al.*. (2003) Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. *Nature* **424**: 556-61 [PMID:12891359]
 46. Liu J, Farmer Jr JD, Lane WS, Friedman J, Weissman I and Schreiber SL. (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. *Cell* **66**: 807-15 [PMID:1715244]
 47. Lu KP and Zhou XZ. (2007) The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. *Nat Rev Mol Cell Biol* **8**: 904-16 [PMID:17878917]
 48. Lu PJ, Wulf G, Zhou XZ, Davies P and Lu KP. (1999) The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. *Nature* **399**: 784-8 [PMID:10391244]
 49. Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, Berth-Jones J, Bjerke J, Christophers E and Knop J *et al.*. (2001) SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. *Br J Dermatol* **144**: 788-94 [PMID:11298538]
 50. Mackman RL, Steadman VA, Dean DK, Jansa P, Poullennec KG, Appleby T, Austin C, Blakemore CA, Cai R and Cannizzaro C *et al.*. (2018) Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle. *J Med Chem* **61**: 9473-9499 [PMID:30074795]
 51. Maestre-Martínez M, Haupt K, Edlich F, Jahreis G, Jarczowski F, Erdmann F, Fischer G and Lücke C. (2010) New structural aspects of FKBP38 activation. *Biol Chem* **391**: 1157-67 [PMID:20707607]
 52. Malouitre S, Dube H, Selwood D and Crompton M. (2009) Mitochondrial targeting of cyclosporin A enables selective inhibition of cyclophilin-D and enhanced cytoprotection after glucose and oxygen deprivation. *Biochem J* **425**: 137-48 [PMID:19832699]
 53. McClements L, Annett S, Yakkundi A, O'Rourke M, Valentine A, Moustafa N, Alqudah A, Simões BM, Furlong F and Short A *et al.*. (2019) FKBP and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4. *BMC Cancer* **19**: 351 [PMID:30975104]
 54. McClements L, Annett S, Yakkundi A and Robson T. (2015) The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases. *Curr Mol Pharmacol* **9**: 165-79 [PMID:25986561]
 55. McClements L, Yakkundi A, Papaspyropoulos A, Harrison H, Ablett MP, Jithesh PV, McKeen HD, Bennett R, Donley C and Kissenpfennig A *et al.*. (2013) Targeting treatment-resistant breast cancer stem cells with FKBP and its peptide derivative, AD-01, via the CD44 pathway. *Clin Cancer Res* **19**: 3881-93 [PMID:23741069]
 56. McKeen HD, McAlpine K, Valentine A, Quinn DJ, McClelland K, Byrne C, O'Rourke M, Young S, Scott CJ and McCarthy HO *et al.*. (2008) A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling. *Endocrinology* **149**: 5724-34 [PMID:18669603]
 57. Nath R. (2017) Peptidyl-prolyl isomerase (PPIase): an emerging area in tumor biology *Cancer Res Front* **3**: 126-143
 58. Nechama M, Kwon J, Wei S, Kyi AT, Welner RS, Ben-Dov IZ, Arredouani MS, Asara JM, Chen CH and Tsai CY *et al.*. (2018) The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation. *Nat Commun* **9**: 1603 [PMID:29686383]
 59. Oh J and Malter JS. (2013) Pin1-FADD interactions regulate Fas-mediated apoptosis in activated eosinophils. *J Immunol* **190**: 4937-45 [PMID:23606538]
 60. Pastorino L, Sun A, Lu PJ, Zhou XZ, Balastik M, Finn G, Wulf G, Lim J, Li SH and Li X *et al.*. (2006) The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. *Nature* **440**: 528-34 [PMID:16554819]
 61. Pinch BJ, Doctor ZM, Nabet B, Browne CM, Seo HS, Mohardt ML, Kozono S, Lian X, Manz TD and Chun Y *et al.*. (2020) Identification of a potent and selective covalent Pin1 inhibitor. *Nat Chem Biol* **16**: 979-987 [PMID:32483379]
 62. Porter Jr GA and Beutner G. (2018) Cyclophilin D, Somehow a Master Regulator of Mitochondrial Function. *Biomolecules* **8** [PMID:30558250]
 63. Pu W, Shen X, Fan X, Zheng Y, Liu X, Li J, Zhou JK, He J, Wei R and Gong Y *et al.*. (2025) Structure-Guided Optimization and Preclinical Evaluation of 6-O-Benzylguanine-Based Pin1 Inhibitor for Hepatocellular Carcinoma Treatment. *J Med Chem* **68**: 2869-2889 [PMID:39868498]
 64. Qiu C, Albayram O, Kondo A, Wang B, Kim N, Arai K, Tsai CY, Bassal MA, Herbert MK and Washida K *et al.*. (2021) Cis P-tau underlies vascular contribution to cognitive impairment and dementia and can be effectively targeted by immunotherapy in mice *Sci Transl Med* [PMID:34078745]

65. Rippmann JF, Hobbie S, Daiber C, Guilliard B, Bauer M, Birk J, Nar H, Garin-Chesa P, Rettig WJ and Schnapp A. (2000) Phosphorylation-dependent proline isomerization catalyzed by Pin1 is essential for tumor cell survival and entry into mitosis. *Cell Growth Differ* **11**: 409-16 [PMID:10939594]
66. Robson T and James IF. (2012) The therapeutic and diagnostic potential of FKBPL; a novel anticancer protein. *Drug Discov Today* **17**: 544-8 [PMID:22265918]
67. Saibil H. (2013) Chaperone machines for protein folding, unfolding and disaggregation. *Nat Rev Mol Cell Biol* **14**: 630-42 [PMID:24026055]
68. Shirane M and Nakayama KI. (2003) Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. *Nat Cell Biol* **5**: 28-37 [PMID:12510191]
69. Shore ER, Awais M, Kershaw NM, Gibson RR, Pandalaneni S, Latawiec D, Wen L, Javed MA, Criddle DN and Berry N *et al.*. (2016) Small Molecule Inhibitors of Cyclophilin D To Protect Mitochondrial Function as a Potential Treatment for Acute Pancreatitis. *J Med Chem* **59**: 2596-611 [PMID:26950392]
70. Stifani S. (2018) The Multiple Roles of Peptidyl Prolyl Isomerases in Brain Cancer. *Biomolecules* **8**: 112 [PMID:30314361]
71. Storer CL, Dickey CA, Galigniana MD, Rein T and Cox MB. (2011) FKBP51 and FKBP52 in signaling and disease. *Trends Endocrinol Metab* **22**: 481-90 [PMID:21889356]
72. Sunnotel O, Hiripi L, Lagan K, McDaid JR, De León JM, Miyagawa Y, Crowe H, Kaluskar S, Ward M and Scullion C *et al.*. (2010) Alterations in the steroid hormone receptor co-chaperone FKBPL are associated with male infertility: a case-control study. *Reprod Biol Endocrinol* **8**: 22 [PMID:20210997]
73. Theuerkorn M, Fischer G and Schiene-Fischer C. (2011) Prolyl cis/trans isomerase signalling pathways in cancer. *Curr Opin Pharmacol* **11**: 281-7 [PMID:21497135]
74. Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L and Dyer H *et al.*. (2011) FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. *Clin Cancer Res* **17**: 1044-56 [PMID:21364036]
75. Waldmeier PC, Feldtrauer JJ, Qian T and Lemasters JJ. (2002) Inhibition of the mitochondrial permeability transition by the nonimmunosuppressive cyclosporin derivative NIM811. *Mol Pharmacol* **62**: 22-9 [PMID:12065751]
76. Warne J, Pryce G, Hill JM, Shi X, Lennerås F, Puentes F, Kip M, Hilditch L, Walker P and Simone MI *et al.*. (2016) Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis. *J Biol Chem* **291**: 4356-73 [PMID:26679998]
77. Wei S, Yoshida N, Finn G, Kozono S, Nechama M, Kyttaris VC, Zhen Zhou X, Tsokos GC and Ping Lu K. (2016) Pin1-Targeted Therapy for Systemic Lupus Erythematosus. *Arthritis Rheumatol* **68**: 2503-13 [PMID:27159270]
78. Yakkundi A, McCallum L, O'Kane A, Dyer H, Worthington J, McKeen HD, McClements L, Elliott C, McCarthy HO and Hirst DG *et al.*. (2013) The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway. *PLoS One* **8**: e55075 [PMID:23457460]
79. Yurchenko V, Constant S, Eisenmesser E and Bukrinsky M. (2010) Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics. *Clin Exp Immunol* **160**: 305-17 [PMID:20345978]
80. Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G, Gu L, Tang X, Lu KP and Xiao ZX. (2002) The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. *Nature* **419**: 849-53 [PMID:12397361]
81. Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M and Henz BM. (2001) The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. *J Allergy Clin Immunol* **108**: 275-80 [PMID:11496246]
82. Šileikytė J and Forte M. (2016) Shutting down the pore: The search for small molecule inhibitors of the mitochondrial permeability transition. *Biochim Biophys Acta* **1857**: 1197-1202 [PMID:26924772]